Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse

Endocrinology

Volumn 150, Issue 2, 2009, Pages 592-599

  Hadjiyanni, Irene ^a   Li, Kunmin Karen ^a   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; JEJUNUM MUCOSA; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; DIABETES MELLITUS, TYPE 1; DRUG EVALUATION, PRECLINICAL; FEMALE; GLUCAGON-LIKE PEPTIDE 2; IMMUNE SYSTEM; INTESTINAL MUCOSA; INTESTINE, SMALL; MICE; MICE, INBRED NOD; ORGAN SIZE; PEPTIDES; PERMEABILITY; PREDIABETIC STATE; TIME FACTORS;

EID: 59649128123     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1228     Document Type: Article

References (38)

1. Hawa MI, Beyan H, Buckley LR, Leslie RD 2002 Impact of genetic and non- genetic factors in type 1 diabetes. Am J Med Genet 115:8-17
2. Atkinson MA, Leiter EH 1999 The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5:601-604
3. Leiter EH 2005 Nonobese diabetic mice and the genetics of diabetes susceptibility. Curr Diab Rep 5:141-148
4. Graham S, Courtois P, Malaisse WJ, Rozing J, Scott FW, Mowat AM 2004 Enteropathy precedes type 1 diabetes in the BB rat. Gut 53:1437-1444
5. Vaarala O 2002 The gut immune system and type 1 diabetes. Ann NY Acad Sci 958:39-46
6. Todd DJ, Forsberg EM, Greiner DL, Mordes JP, Rossini AA, Bortell R 2004 Deficiencies in gut NK cell number and function precede diabetes onset in BB rats. J Immunol 172:5356-5362
7. Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E 2003 Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes 52:2287-2295
8. Neu J, Reverte CM, Mackey AD, Liboni K, Tuhacek-Tenace LM, Hatch M, Li N, Caicedo RA, Schatz DA, Atkinson M 2005 Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. J Pediatr Gastroenterol Nutr 40:589-595
9. Watts T, Berti I, Sapone A, GerarduzziT, NotT, Zielke R, Fasano A 2005 Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci USA 102:2916-2921
10. Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, Lampis R, Kryszak D, Carteni M, Generoso M, Iafusco D, Prisco F, Laghi F, Riegler G, Carratu R, Counts D, Fasano A 2006 Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55:1443-1449
11. Meddings JB, Jarand J, Urbanski SJ, Hardin J, Gall DG 1999 Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol 276:G951-G957
12. Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, Piemonti L, Pastore MR, Paroni R 2006 Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49:2824-2827
13. Estall JL, Drucker DJ 2006 Glucagon-like Peptide-2. Annu Rev Nutr 26: 391-411
14. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH 2000 Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47:112-119
15. Cameron HL, Perdue MH 2005 Stress impairs murine intestinal barrier function: improvement by glucagon-like Peptide-2. J Pharmacol Exp Ther 314:214-220
16. Cameron HL, Yang PC, Perdue MH 2003 Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy. Am J Physiol Gastrointest Liver Physiol 284:G905-G912
17. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, DeForest L, Cooper S, Brubaker PL 1997 Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15:673-677
18. Poussier P, Ning T, Murphy T, Dabrowski D, Ramanathan S 2005 Impaired post-thymic development of regulatory CD4 + 25+ T cells contributes to diabetes pathogenesis in BB rats. J Immunol 174:4081-4089
19. Tsai C-H, Hill M, Drucker DJ 1997 Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 272:G662-G668
20. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ 2008 Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338-1349
21. Ogawa N, List JF, Habener JF, Maki T 2004 Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53:1700-1705
22. Baglole CJ, Sigalet DL, Martin GR, Yao S, Meddings JB 2006 Acute denervation alters the epithelial response to adrenoceptor activation through an increase in α1-adrenoceptor expression on villus enterocytes. Br J Pharmacol 147:101-108
23. Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH 2007 Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 56:1522-1528
24. Ounissi-Benkalha H, Polychronakos C 2008 The molecular genetics of type 1 diabetes: new genes and emerging mechanisms. Trends Mol Med 14:268-275
25. Peng H, Hagopian W 2006 Environmental factors in the development of type 1 diabetes. Rev Endocr Metab Disord 7:149-162
26. Lefebvre DE, Powell KL, Strom A, Scott FW 2006 Dietary proteins as environmental modifiers of type 1 diabetes mellitus. Annu Rev Nutr 26:175-202
27. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC 2002 Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 34:385-396
28. Fasano A,Shea-Donohue T 2005 Mechanismsofdisease: theroleofintestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2:416-422
29. Mooradian AD, Morley JE, Levine AS, Prigge WF, Gebhard RL 1986 Abnormal intestinal permeability to sugars in diabetes mellitus. Diabetologia 29:221-224
30. Carratu R, Secondulfo M, de Magistris L, Iafusco D, Urio A, Carbone MG, Pontoni G, Carteni M, Prisco F 1999 Altered intestinal permeability to mannitol in diabetes mellitus type I. J Pediatr Gastroenterol Nutr 28:264-269
31. Secondulfo M, Iafusco D, Carratu R, deMagistris L, Sapone A, Generoso M, Mezzogiomo A, Sasso FC, Carteni M, De Rosa R, Prisco F, Esposito V 2004 Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig Liver Dis 36:35-45
32. Schuppan D, Hahn EG 2001 Celiac disease and its link to type 1 diabetes mellitus. J Pediatr Endocrinol Metab 14(Suppl 1):597-605
33. Maurano F, Mazzarella G, Luongo D, Stefanile R, D'Arienzo R, Rossi M, Auricchio S, Troncone R 2005 Small intestinal enteropathy in non-obese diabetic mice fed a diet containing wheat. Diabetologia 48:931-937
34. Courtois P, Nsimba G, Jijakli H, Sener A, Scott FW, Malaisse WJ 2005 Gut permeability and intestinal mucins, invertase, and peroxidase in control and diabetes-prone BB rats fed either a protective or a diabetogenic diet. Dig Dis Sci 50:266-275
35. Boushey RP, Yusta B, Drucker DJ 1999 Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277:E937-E947
36. Boushey RP, Yusta B, Drucker DJ 2001 Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 61:687-693
37. Kouris GJ, Liu Q, Rossi H, Djuricin G, Gattuso P, Nathan C, Weinstein RA, PrinzRA2001 Theeffectofglucagon-likepeptide2 onintestinalpermeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 181:571-575
38. Mardini HE, de Villiers WJ 2008 Teduglutide in intestinal adaptation and repair: light at the end of the tunnel. Expert Opin Investig Drugs 17:945-951